New brain cancer drug combo tested for first time in humans

NCT ID NCT07185880

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 24 times

Summary

This early-phase study tests a new drug called MT-125 given alongside standard radiation for people with a newly diagnosed, aggressive brain tumor called glioblastoma. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 and older with a specific type of glioblastoma (IDH wild-type, MGMT-unmethylated) can join. This is the first time MT-125 is being tested in humans, so its safety and effectiveness are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic Hospital

    RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic Hospital

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic Hospital

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.